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Pharmacokinetic studies have made many significant contributions to rational therapeutics in children. Pharmacokinetic data have helped distinguish
between differences in drug disposition and drug sensitivity in children as compared to adults and led to the establishment of age-specific dosage
guidelines. Factors influencing the observed differences between drug disposition in children and adults are reviewed. Specific examples utilizing
anticancer drugs are presented. The use of model substrates to study hepatic drug metabolism and renal excretion in children is described and
some results are discussed. The significance of genetic polymorphic drug metabolism is presented and the use of model substrates to determine
individual metabolic phenotypes is described. The use of pharmacokinetic data to define the maximum-tolerated systemic exposure rather than the
maximum-tolerated dosage of anticancer drugs in children is presented. - Environ Health Perspect 102(Suppl 11):11 1-1 18 (1994)
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Introduction
The application ofpharmacokinetic princi-
ples and drug assay technology has been of
significant benefit in recent therapeutic
advances in pediatrics. Pharmacokinetics
has aided in the detection and elucidation
ofthe mechanism of numerous drug-drug
and drug-disease interactions, the
refinement ofspecific pediatric dosages of
many drugs, and more specific individual-
ization oftherapy for children with a wide
variety ofdiseases. The last decade has seen
the development of rapid, sensitive, and
specific assays for many drugs along with
refinement of pharmacokinetic study
design and use ofsophisticated computer-
ized modeling approaches that make
optimal use oflimited data. These develop-
ments have enhanced the ability to con-
duct comprehensive pharmacokinetic
studies to define the population pharmaco-
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kinetics ofdrugs in the pediatric popula-
tion and clinical monitoring studies to
define the optimal use of measured drug
concentrations in serum or plasma and to
individualize drug therapy. This is impor-
tant because for ethical reasons clinical
studies ofdrugs can rarely be carried out in
healthy volunteer children. For drugs used
primarily in pediatrics, limited data from
adults may be available. As a result, phar-
macokinetic studies must often be per-
formed on sick children under treatment
when a variety oflogistical factors (limited
access to blood samples, limited volume of
blood samples, etc.) as well as ethical con-
cerns make performance of such studies
difficult. Therefore, it is not surprising
that, compared to adults, the amount of
pediatric pharmacokinetic data available
for many drugs is quite limited and for
other drugs there is no pediatric informa-
tion available at all. Despite these limita-
tions, thorough pharmacokinetic studies of
a number ofdrugs in children have yielded
some very useful data.
There are a number of reasons that
pharmacokinetic data must be generated
from studies in children rather than simply
extrapolating from adult studies. First,
children are not simply miniature adults.
There are a number of physiologic and
metabolic processes which differ qualita-
tively as well as quantitatively when com-
pared to adults. Different metabolic
pathways may predominate in the bio-
transformation ofsome drugs, for example.
Children often receive treatment for differ-
ent diseases that don't afflict adults. This
may require treatment with different drugs
or drug combinations than are typically
used in adults. In addition, the pathophysi-
ology ofthe disease may affect the disposi-
tion ofthese drugs. Finally, children may
have different inherent sensitivity to drug
effects, yielding significantly different
dose-response or dose-toxicity curves.
Pharmacokinetic data help differentiate
between drug disposition differences that
may be responsible for alterations in the
dose-response relationship and inherent
differences in drug-receptor interactions.
In the latter case, altered concentration-
response relationships may be identified.
This review will discuss the use ofphar-
macokinetic data in children other than
neonates or infants. For purposes of this
discussion, the definition of age ranges
used by the National Library ofMedicine's
Index Medicus will be observed. Neonates
are defined as less than 1 month of age,
and infants are defined as 1 to 23 months
of age. Children are 2 to 12 years of age,
while adolescents are 13 to 18 years old.
This discussion will focus on the latter two
groups, pediatric patients from 2 to 18
years old.
Physiologic Factors InfluencingDrug
Disposition inChildren
Absorption. Absorption ofdrugs from the
gastrointestinal tract is influenced by fac-
tors such as gastric acidity, gastric and
intestinal motility, enzymatic activity, per-
meability and maturation of the mucosal
membrane, biliary function, bacterial flora,
and dietary components (1). Although
many of these factors undergo significant
maturational changes during the first 2
years oflife, less is known about changes
between 2 and 18 years ofage. In general,
younger children may have higher gastric
pH and increased gastric and intestinal
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Figure 1. Developmental changes in total body water, intracellular and extracellular water, body fat, and kidney
function in infants and children expressed as percentages of body weight and adultvalues. From Milsap et al. (1);
reprinted with permission.
There is also substantial interpatient
variability in the activity ofthese pathways
for children of the same age. This may
translate into 2- to 3-fold variability in the
systemic clearance ofsome drugs, even in
children with no underlying pathophysiol-
ogy that might affect drug disposition. In
addition, some pathways may be com-
pletely absent in a subset ofindividuals as a
result ofa genetic defect (2). This yields a
multimodal distribution ofdrug clearance
with significantly lower clearances and
much higher drug concentrations in
patients who lack the enzyme required to
metabolize compounds by that pathway.
Such polymorphic drug metabolism can
result in potentially lethal drug exposure
following normal therapeutic dosages in
patients who are genetically poor metabo-
lizers.
Exeretion. Renal function increases
over the first year oflife, but it is essentially
at adult (corrected for body size) level by
the age of 1 year and remains constant over
the pediatric and adolescent age range, as
shown in Figure 1. Thus, there is no gen-
eral age-related change in renal function
over this age period. However, there is sub-
stantial variability in renal function within
the general population, and the kidneys are
very sensitive to the toxic effects ofa num-
ber ofdrugs. This can result in decreased
renal function and clearance ofa number
ofcompounds or potentially toxic metabo-
lites excreted in the urine. For those com-
pounds primarily excreted in the urine, this
can result in increased exposure and likeli-
hood of toxicity in patients with reduced
renal function. Unlike metabolic function,
a number ofmethods have been developed
that reliably and accurately estimate
glomerular filtration rate (GFR). These
estimates of GFR can be used to individu-
alize the dosage of drugs and thereby
increase the likelihood of efficacy and
reduce the chances of toxicity in an indi-
vidual patient.
Effects ofDisease. In both children
and adults, underlying diseases may affect
the disposition ofdrugs. This has been far
more extensively studied in adults than
children. The most well-documented dif-
ferences in drug disposition secondary to
an underlying disease occur in children
with cystic fibrosis. For most drugs studied,
clearance is faster in children with cystic
fibrosis than in healthy children or those
treated for other conditions. As a result,
higher dosages are required for children
with cystic fibrosis both to yield a thera-
peutic benefit and to achieve similar serum
drug concentrations as in children who do
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not have this disease. This subject recently
has been reviewed extensively (3). It has
also been suggested that at least part ofthis
apparent difference in clearance may be an
artifact secondary to normalizing clearance
to body weight or surface area, because
children with cystic fibrosis are often
smaller and have less total body fat than
other children (4). Therefore, although
absolute clearance values may be similar in
age- and sex-matched subjects with and
without cystic fibrosis, clearances normal-
ized to body weight or body surface area
are larger in subjects with cystic fibrosis
because they are smaller. However, other
data suggest that differences in clearance
persist even when clearances are normal-
ized to ideal body weight or are left unnor-
malized (5). Several mechanisms may
contribute to this apparently increased
clearance, but the exact mechanism(s)
responsible have not been established for
any specific drugs.
Normalization of
Pharnacokinetic Parameters
As discussed above, in pediatric pharmaco-
kinetic studies it is necessary to normalize
clearance and volume ofdistribution para-
meters to body size in order to compare
values in children of different ages. The
most common methods are to normalize
these parameters to total bodyweight, ideal
or lean body weight, or body surface area.
Body surface area is generally not measured
directly but calculated from one ofseveral
equations that require body weight and
height (6-10). The goal ofnormalization
is to correct for differences in parameters
that are due solely to differences in body
size. After normalization, these parameters
are usually uncorrelated with age. We have
found for several drugs that normalization
to body surface area eliminates more ofthe
age-related differences in clearance than
normalization to body weight (11,12).
This suggests that dosages based on body
surface area will result in less variability
in serum drug concentrations than dosages
based on body weight. However, the
opposite might be true for other drugs,
depending on their route(s) ofbiotransfor-
mation or excretion and protein and tissue
binding.
Several equations are available for cal-
culation ofbody surface area (Table 1). All
of them have the same general form but
use different coefficients and exponents.
Although the oldest ofthese equations (6)
is widely used in pediatrics, it yields biased
results, particularly in very small or young
children, probably because very few young
Table 1. Body surface area equations.
Dubois-Dubois (6) (Surface area [SA] = 0.007184 x height [ht]0725x weight[Wt]042)
Boyd (7) (SA = 0.017827 x ht0.500 x wt0.4838)
Gehan-George (8) (SA = 0.02350 x ht0.42246 X Wt0.51456)
Haycock (9) (SA = 0.024265 x ht 0.3964 X Wt 0.5378
Where SA is in square meters, height is in centimeters, and weight is in kilograms.
Table 2. Maximally tolerated doses (MTD) of some anticancer drugs in adults and children.
MTD, mg/m2 MTD ratio
Drug Schedule Children Adults children:adults
Dianhydrogalactitiol qd x 5 days 25 30 0.83
5-Azacytidine qd x 5 days 200 225 0.89
Piperazinedione qd x 5 days 3 3 1.0
Etoposide (VP-16) Biweekly 150 125 1.20
Diglycoaldehyde qd x 5 days 7,500 6,000 1.25
Amsacrine qd x 5 days 50 40 1.25
Daunomycin (mg/kg) qd x 4 days 1.0 0.8 1.25
Doxorubicin qd x 4 days 0.8 0.6 1.33
Teniposide (VM-26) (mg/kg) Biweekly 4.0 3.0 1.33
3-Deazauridine (leukemia patients) qd x 5 days 8.2 6.0 1.40
Azaserine (mg/kg, total dose) Daily 156 108 1.44
Dihydroxyanthracenedione Every 3 weeks 18 12 1.5
3-Deazauridine (solid tumors) qd x 5 days 2.8 1.5 1.85
Cyclocytidine qd x 10 days 600 300 2.00
ICRF-187 qd x 3 days >2750 1,250 >2.20
qd, once daily.
individuals were used in the study popula-
tion from which this equation was derived.
The Haycock and Gehan-George equa-
tions yield very similar results. We recom-
mend the Gehan-George equation,
however, because it is based on direct mea-
surements in over 400 subjects, including
both children and adults. The Haycock
equation is based on direct measurements
in 81 pediatric subjects.
E ples
Anticaneer Drugs. Anticancer drugs pro-
vide a useful model for assessing important
differences in pharmacokinetic disposition
between children and adults, particularly
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Figure 2. Methotrexate systemic clearance versus
age in years; pediatric subjects()); adult subjects (o).
From Evans et al. (12); reprinted with permission.
with regard to environmental exposure to
toxins. Anticancer drugs are generally
administered at their maximum tolerated
dosage (MTD), at which significant sys-
temic toxicity may be anticipated. As sum-
marized in Table 2, for many anticancer
drugs the MTD in children is greater than
for adults (13,14). This may be due to
faster clearance of some compounds,
decreased sensitivity to the toxic effects, or
both. Differences in clearance may be the
result ofgreater organ reserve (i.e., better
kidney and liver function) in children,
compared to adults who have been exposed
to other drugs or toxins that may damage
these organs. In general, however, children
are often able to tolerate higher dosages (on
amg/mi2 basis) than adults.
One example ofsomewhat greater drug
clearance in children than adults is the dis-
position of methotrexate. As shown in
Figure 2, children as a group have faster
methotrexate clearance than adults, and
there is a general trend toward decreasing
methotrexate clearance with increasing age.
However, it is apparent from Figure 2, that
there is substantial variability at any individ-
ual age, and clearance values in children and
adults overlap somewhat. The trend toward
decreasing clearance in older patients is
probably due to progressive decrease in renal
function with increasing age.
We have seen similar trends for clear-
ance normalized to body weight with other
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anticancer drugs (15,12). Because some of
these drugs are not excreted renally to a
significant degree, it is likely that other
mechanisms such as distribution in body
tissues is at least partly responsible for
faster clearances in younger children than
in adolescents or adults.
Model Substrates. In recent years, the
use ofmodel substrates to determine drug
clearance by specific elimination pathways
has been developed. Specifically, our group
has conducted studies with lorazepam,
antipyrine, and indocyanine green to study
hepatic drug clearance mechanisms (11)
and technetium-99m diethylenetriamine
pentaacotic acid to measure glomerular
filtration rate in children (16). This
approach has the advantages ofbeing able
to study specific drug-metabolizing path-
ways using low (nontherapeutic) doses of
relatively safe substances in large numbers
of pediatric patients. This provides valu-
able information about hepatic function
without exposing the children to poten-
tially toxic effects of drugs. Lorazepam,
indocyanine green, and antipyrine are
administered simultaneously as a 5-min iv
infusion as an assessment ofglucuronida-
tion (lorazepam), which is removal ofhigh
extraction ratio drugs (indocyanine green),
and hepatic mixed-function oxidase activity
(antipyrine), as shown in Figure 3.
We have observed that clearance oftwo
of these model substrates, indocyanine
green (17) and antipyrine (18), is corre-
lated with age when clearance is normal-
ized to body weight (ml/min/kg). Younger
children have faster clearance than adoles-
cents or young adults (Figures 4,5). There
is no difference in clearance among these
three groups when clearance is normalized
to body surface area (ml/min/m2). No dif-
ferences were seen in lorazepam clearance
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GLUCURONIDATION
NDOCYANINE GREE
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Taken up by the hepato
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Ever blood flow
LIVER BLOOD FL
among these three groups when clearance
was normalized by either method (18).
These results suggest that, for drugs elimi-
nated by similar pathways to antipyrine
and indocyanine green (hepatic microso-
mal metabolism and high-extraction ratio
compounds), dosages based on body
weight will yield lower serum concentra-
tions in younger children, while dosages
based on body surface area are more likely
to result in similar concentrations in chil-
dren and adults. One explanation for this
result is the observation (Figure 6) that
liver volume, estimated by ultrasound stud-
ies, is similar in children and adults when
expressed as a percentage ofbody surface
area but is greater in children when nor-
malized to body weight, and the ratio of
liver volume to weight decreases with
increasing age. It has been suggested
(17,18) that for several drugs, including
antipyrine, "functional hepatic parenchy-
mal mass," which approximates to liver
volume, is a major determinant ofhepatic
drug metabolism. Our results suggest that
this relationship may also be true for indo-
cyanine green but that lorazepam is not
dependent on functional hepatic parenchy-
mal mass.
We have also used this methodology to
study drug clearance in patients with cystic
fibrosis (5). As mentioned earlier, patients
with this disease have faster clearance for
many drugs and require larger dosages to
achieve equivalent clinical results. We com-
pared results in nine patients with cancer
who were treated onlywith surgery or radi-
ation not involving the liver to 14 patients
with cystic fibrosis. In this study, results
were compared for unnormalized clearance
as well as clearances normalized to body
weight and body surface area. Antipyrine
clearances were not different between the
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Figure 3. Summary of hepatic transformation routes for lorazepam, indocyanine green, and antipyrine.
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Figure 4. Comparison of indocyanine green plasma
clearance and volume of distribution (both normalized
to body weight) and half-life for 85 children under 10
years old (0.9-9.9 years), 30 adolescents between 10
and 19 years (10.2-17.8 years), and nine adults (21-33
years). Each bar depicts the mean (-) plus one stan-
dard deviation above and below the mean for each
parameter. Plasma clearance normalized to body
weight (ml/min/kg) was significantly different between
all children and adults (14.8 versus 10.6; p= 0.0006),
and between children less than 10 years of age and
adults (15.6 versus 10.6; p= 0.0001). From Evans et al.
(17); reprinted with permission.
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Figure 5. Mean antipyrine clearance normalized to both
weight and body surface area for the two age groups of
children and the adult volunteers. The bars represent one
standard deviation above and below the mean for each
group. From Crometal. (18); reprintedwith permission.
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Figure6. Relation between livervolume, bodyweight, and
age based on published data. Liver volume was deter-
mined in each study by ultrasound scan. Single points )
represent individual patients, standard deviations are
shown by solid brackets, and ranges are shown by broken
lines when individual patient data were not published.
From Evansetal.(17); reprintedwith permisssion.
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two groups, regardless of the method of
normalization. However, lorazepam and
indocyanine green clearances were
significantly faster in the patients with cys-
tic fibrosis. These results for lorazepam are
consistent with increased glucuronidation
activity, which has been demonstrated in
experimentally induced cholestasis (19,20).
The mechanism underlying the increased
clearance of indocyanine green has not
been elucidated.
Similarly, we demonstrated a signifi-
cantly faster clearance, normalized to body
weight, of lorazepam in six moderately
malnourished children with acute lympho-
cytic leukemia, compared to 13 well-nour-
ished matched controls with acute
lymphocytic leukemia (21). The malnour-
ished children also had a shorter terminal
lorazepam half-life. However, clearances
normalized to body surface area were not
significantly different between the two
groups. As with the patients with cystic
fibrosis, it is possible that this may partly
be due to the decreased body size ofchil-
dren who are malnourished. This may be
particularly important when clearances are
normalized to body weight. These results
need to be further studied and confirmed.
In summary, model substrates are use-
ful in comparing groups of children with
different diseases to determine the effect of
disease states on specific drug metabolism
pathways. In addition, model substrates
can help explain changes in drug metabo-
lism during growth and maturation.
Polymorphic DrugMetabolism. It has
been recognized for some time that for cer-
tain drug-metabolizing enzymes, a stable
percentage of the population lacks or has
greatly reduced enzyme activity (2,22).
The first such genetic polymorphism to be
described was N-acetylation. More
recently, debrisoquin-sparteine oxidation
and mephenytoin oxidation have been
described. The debrisoquin hydroxylase
deficiency has important potential clinical
significance because over 30 other drugs
have been identified as substrates for this
enzyme. In addition, it is a fairly rare
deficiency, with only about 5% of
Caucasians classified as poor metabolizers
(PMs) of this enzyme. In contrast, about
50% of Caucasians, 10% ofJapanese, 5%
of Canadian Eskimos, and 80 to 90% of
Egyptians and Moroccans are slow acetyla-
tors. Because both ofthese polymorphisms
can have serious adverse effects in children
treated with conventional doses of drugs
metabolized by one of the affected
enzymes, we have developed a simple
method to simultaneously phenotype
patients for both these polymorphisms
(23). This method involves administration
ofdextromethorphan, an over-the-counter
antitussive that is a substrate for debriso-
quin hydroxylase, and caffeine, an ingredi-
ent in Coca-Cola whose metabolite is a
substrate for N-acetyltransferase. Urine is
then collected over the next 4 hr, and the
ratio ofdextromethorphan to its metabo-
lite, dextrorphan, in urine is determined to
assign debrisoquin hydroxylase metabolizer
phenotype. Similarly, the ratio of 5-acetyl-
amino-6-formylamino-3-methyluracil to 1-
methylxanthine, two metabolites of
caffeine, is determined to assign acetylator
phenotype. This method has been shown
to be a reliable, innocuous, and noninva-
sive way to assess polymorphic drug metab-
olism in variouspediatric populations (23).
Recently, this method has been used to
demonstrate a lower prevalence of the
debrisoquin oxidative PM phenotype in
African-American subjects, compared to a
comparable group of white subjects, as
shown in Figure 7 (24). This study
demonstrated a prevalence ofthe PM phe-
notype of7.7% in 480 white subjects com-
pared to 1.9% in 106 African-American
subjects (p= 0.029). This difference sug-
gests that differences in efficacy or toxicity
may be seen in African-American versus
white patients for drugs metabolized by
this enzyme. There may also be differences
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in the incidence ofcertain diseases associ-
ated with the debrisoquin oxidative pheno-
type between these racial groups.
This study demonstrates how such
innocuous model substrates can be used to
determine the metabolic phenotype of a
large population and to characterize differ-
ences between ethnic or geographic groups.
In addition, this fast but relatively inexpen-
sive method can be used to identify the
small proportion ofindividuals who may be
at risk ofexcessive toxicity for some drugs
administered at conventional dosages.
Additional studies are underway to further
characterize the prevalence of the debriso-
quin PM phenotype in other populations.
Pharmacodynamic Studies ofAnti-
cancer Drugs. The interpatient variability
in the disposition ofmany drugs, including
anticancer drugs, is a variable which con-
founds interpretation ofphase I drug stud-
ies designed to determine the MTD and
the dosage used in phase II studies (23).
Figure 8 depicts the effect ofa 3-fold range
in clearance (which is quite common in
children) of a hypothetical drug adminis-
tered to all patients at a fixed dosage on the
therapeutic or toxic effects of the drug.
Although all subjects receive the same
dosage ofthe drug, interindividual variabil-
ity in clearance results in significantly dif-
ferent effects, as predicted by the
hypothetical exposure versus effect curves.
-4.8 -4.4 -4.0 -3.6 -32 -2.8 -2.4 -2.0 -t6 -1.2 -0.8 -0.4 0.0 0.4 0.8 1.2 16
log /DT
Figure 7. Frequency distribution (expressed as a percent of each racial group) for metabolic ratio of dextromethor-
phan to dextrorphan in 480 white (top panel) and 106African-American (bottom panel) unrelated children. The dif-
ference in the prevalence of the poor metabolizer phenotype (shown in solid bars) between white subjects (7.7%)
and African-American subjects (1.9%) is significant (p= 0.029) (24).
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Figure 8. The maximum-tolerated systemic exposure
concept for phase trials compared to the maximum-
tolerated dosage (MTD) approach for a hypothetical
drug with an MTD = 300 mg/M2 and a 3-fold range in
drug clearance among different patients (28).
For this reason, our group (25-28) has
advocated the design ofphase I studies to
define the maximum tolerated systemic
exposure rather than the MTD and for
phase II studies to be conducted by using
pharmacokinetic data and principles to
adjust dosages to achieve a target systemic
exposure rather than administering a fixed
dosage to all patients. As shown in Figure
8, when this approach is used successfully,
the interpatient variability in drug disposi-
tion can be adjusted for and the actual sys-
temic exposure (defined as the area under
the concentration-time curve or area-
under-the-curve [AUC]) will be much less
variable than in fixed-dosage studies. This
approach has been described in detail (28)
and several studies using this design are
currently underway.
Conclusions
Well-designed, carefully conducted phar-
macokinetic studies can contribute a great
deal to our knowledge of how to most
appropriately use drugs in children.
Children have unique physiologic and
pathologic characteristics that distinguish
them from adults, but in general, drug dis-
position is more variable than in adults,
and, on average, children have faster clear-
ances ofmany drugs and can tolerate larger
dosages (based on body size) than adults.
Pharmacokinetic parameters normalized to
body surface area usually are less correlated
with age than parameters normalized to
body weight, suggesting that dosages based
on body surface area will yield more consis-
tent serum concentrations and therapeutic
or toxic effects than dosages based on body
weight. Model substrates are useful tools
for noninvasively probing differences in
drug disposition and identifying genetic
polymorphisms. Drug disposition in chil-
dren is highly variable and therefore dose-
ranging studies must use pharmaco-
kinetics to identify the optimal dosages of
drugs administered near their maximum
tolerated dosage. Other important differ-
ences in drug disposition between children
and adults remain to be studied.
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